Shanghai Pharmaceuticals Holding (SHA:601607, HKG:2607) received approval to market its aripiprazole tablets in the Philippines after obtaining a drug registration certificate, according to a Saturday filing on the Shanghai bourse.
The Chinese pharmaceutical company's Shanghai shares rose less than 1% during Monday's midday trade.
The drug is mainly used to treat schizophrenia and manic episodes of bipolar disorder. The antipsychotic drug can also be used as adjunctive therapy for depression.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.